File this under “Up, up and away!”

Spending on cancer medicines in the U.S. has doubled since 2012, reaching nearly $50 billion last year, thanks to a recent rush of new treatments that were launched at high prices. And this may be only the beginning: Spending is expected to roughly double — to $100 billion — by 2022, or from 12 percent to 15 percent annually, according to a new analysis.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • From the closing paragraph – “Looking more broadly, IQVIA found ….” given the current state of the news, might it be more appropriate to use “IQVIA says they found …” since their numbers can be ‘a bit off?’ Admittedly, Commissioner G used different wording but one wonders about their numbers.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy